CompletedNot Applicable

Effect of Sensory Integration Therapy on Gait Variability and Quality Of Life in Patients With Multiple Sclerosis

Egypt38 participantsStarted 2026-02-05

Plain-language summary

This study aims to evaluate the impact of sensory integration therapy on individuals with multiple sclerosis (MS) by examining its effects on gait variability and overall quality of life.

Who can participate

Age range

18 Years – 45 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male and female patients diagnosed with MS of relapsing-remitting at least 1 year before this study. * The Patient's age will range from 18-45. * A stable MS disease without any episodes of relapse within three months before the study. * The Expanded Disability Status Scale (EDSS) scale from medical documentation (2-4.5) involve that patients have (visual, cerebellum, pyramidal brainstem and sensory) problems. * Ability to walk six minutes' walk test (6 min walk test) Exclusion Criteria: * Orthopedic disorders such as contracture deformities that could negatively affect gait. * Other disorders affect gait and quality of life as (diabetes mellitus). * Other diseases that affect Visual and vestibular problems system (such as vestibular neuritis). * Marked spasticity grade (2,3,4) for bilateral lower extremities according to modified ashworth scale. * Pregnancy.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1This trial studied sensory integration therapy's effect on gait variability in people with MS — can you explain what sensory integration therapy actually involves, and whether the improvements in walking steadiness and speed that were measured here would be relevant to my specific walking difficulties?
2The trial is completed but I don't see published results yet — have you seen any findings from this study, and what do the gait measurements like step length variability and single support time actually tell us about real-world walking ability for someone in my situation?
3The trial used both lab-based gait testing and smartphone-based assessments to measure walking — does that suggest this type of therapy could realistically be monitored at home, and is that something worth discussing as part of my current care plan?
4Since this was a Phase N/A study focused on measuring outcomes rather than comparing to a drug treatment, how does sensory integration therapy fit alongside the disease-modifying therapies I might already be on or considering?
5Are there standard rehabilitation approaches for MS-related walking problems that are already well-supported by evidence, and how would you compare those to something like sensory integration therapy before I consider pursuing it?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Step Length Variability

Timeframe: 20 weeks

Step cycle Variability

Timeframe: 20 weeks

Walking Speed Variability

Timeframe: 20 weeks

Single Support Time Variability (Time on Each Foot)

Timeframe: 20 weeks

Coefficient of Variability of Gait (on each foot)

Timeframe: 20 weeks

Ambulation Index

Timeframe: 20 weeks

Step Length Variability (Smartphone-Based Assessment)

Timeframe: 20 weeks

Gait Velocity Variability (Smartphone-Based Assessment)

Timeframe: 20 weeks

Trial details

NCT IDNCT07390201

SponsorCairo University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-07-20

View on ClinicalTrials.gov More Multiple Sclerosis trials

Who can participate

Age range

18 Years – 45 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Step Length Variability

Timeframe: 20 weeks

Step cycle Variability

Timeframe: 20 weeks

Walking Speed Variability

Timeframe: 20 weeks

Single Support Time Variability (Time on Each Foot)

Timeframe: 20 weeks

Coefficient of Variability of Gait (on each foot)

Timeframe: 20 weeks

Ambulation Index

Timeframe: 20 weeks

Step Length Variability (Smartphone-Based Assessment)

Timeframe: 20 weeks

Gait Velocity Variability (Smartphone-Based Assessment)

Timeframe: 20 weeks